News

Roquette and Bonumose Sign a Global Cooperation Agreement Supporting Tagatose Growth

Roquette, a global leader in plant-based ingredients and a leading provider of pharmaceutical excipients, and Bonumose, a pioneer in enzymatic solutions for rare monosaccharide production, are pleased to announce the signing of a Cooperation Agreement that aims to advance the development of tagatose, a natural-origin sweetener with clinically proven health benefits.

This collaboration combines Roquette’s extensive experience in starch and starch-based sweetener production with Bonumose’s cutting-edge enzymatic technology. By leveraging the strengths of both companies, the agreement aims to enhance the scalability of tagatose, reaffirming Roquette’s commitment to innovative sugar management solutions.

“Roquette is proud to partner with Bonumose to advance tagatose growth,” expresses Anne Hirsch, Head of Sugar Management at Roquette. “We recognize the potential of Bonumose’s innovative enzyme technology, which produces high-purity tagatose. Our large-scale starch sweetener production expertise can significantly enhance processing efficiency post enzymatic conversion. This partnership aligns with our long-term vision of sustainable production and meeting the growing global demand for sweetening solutions.”

Ed Rogers, CEO of Bonumose, adds: “Tagatose closely matches the taste, flavor, and cookability of white sugar while offering health benefits such as reduced calories and an ultra-low glycemic index. We are excited to collaborate with Roquette, given their engineering prowess, and multiple market routes. We are happy to welcome Roquette into our expanding ecosystem of strategic partners supporting tagatose adoption.”

Read more here.

Recent News

04/22/2026

RIVANNA expands multi-site clinical study for Accuro XV musculoskeletal imaging system

RIVANNA®, developer of AI-enabled clinical decision-support solutions, announced that it has expanded its clinical studies evaluating Accuro® XV, the company’s musculoskeletal imaging system, from two to eight sites nationwide. This expansion follows execution of a funding option by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response

04/22/2026

Luminoah Announces FDA Clearance of the Luminoah Flow Enteral Nutrition System, A Brighter Future for Tube Feeding

Luminoah, a medical technology company focused on modernizing enteral nutrition, today announced it has received U.S. Food and Drug Administration clearance for Luminoah Flow™, an enteral feeding system designed to improve the experience of patients who rely on tube feeding. Luminoah Flow combines portability, precision, and connected technology into a streamlined system designed for both

04/21/2026

GO Virginia Region 7 funds LIFT-VA

On Tuesday, March 24, 2026, GO Virginia Region 7 funded something the Commonwealth has not had before: a structured, credentialed pathway that takes students from their first day in a real biotechnology laboratory all the way to a career in one of the fastest-growing industries in America. The program is called Life-Sciences Innovation & Future